DOCSLIB.ORG

Listed for Sale: Analyzing Data on Fentanyl, Fentanyl Analogs and Other Novel Synthetic Opioids on One Cryptomarket T

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Listed for Sale: Analyzing Data on Fentanyl, Fentanyl Analogs and Other Novel Synthetic Opioids on One Cryptomarket T Drug and Alcohol Dependence 213 (2020) 108115 Contents lists available at ScienceDirect Drug and Alcohol Dependence journal homepage: www.elsevier.com/locate/drugalcdep Full length article Listed for sale: Analyzing data on fentanyl, fentanyl analogs and other novel synthetic opioids on one cryptomarket T Francois R. Lamya,*, Raminta Daniulaityteb, Monica J. Barrattc,d, Usha Lokalae, Amit Shethf, Robert G. Carlsong a Department of Society and Health, Faculty of Social Sciences and Humanities, Mahidol University, Salaya, Thailand b College of Health Solutions, Arizona State University, Phoenix, AZ, United States c Social and Global Studies Centre, RMIT University, Melbourne, VIC, Australia d National Drug and Alcohol Research Centre, UNSW Sydney, NSW, Australia e Kno.e.sis Center, Department of Computer Science, Wright State University, Dayton, OH, United States f Artificial Intelligence Center, University of South Carolina, Columbia, SC, United States g Center for Interventions, Treatment, and Addictions Research, Department of Population and Public Health Sciences, Wright State University, Dayton, OH, United States ARTICLE INFO ABSTRACT Keywords: Background: The United States is facing a "triple wave" epidemic fueled by novel synthetic opioids. Cryptomarkets Cryptomarkets, anonymous marketplaces located on the deep web, play an increasingly important role in the Darknet markets distribution of illicit substances. This article presents the data collected and processed by the eDarkTrends Fentanyl platform concerning the availability trends of novel synthetic opioids listed on one cryptomarket. Fentanyl analogs Methods: Listings from the DreamMarket cryptomarket "Opioids" and "Research Chemicals" sections were col- Synthetic opioids lected between March 2018 and January 2019. Collected data were processed using eDarkTrends Named Entity Recognition algorithm to identify opioid drugs, and to analyze their availability trends in terms of frequency of listings, available average weights, average prices, and geographic indicators of shipment origin and destination information. Results: 95,011 opioid-related listings were collected through 26 crawling sessions. 33 novel synthetic opioids were identified in 3.3 % of the collected listings. 44.7 % of these listings advertised fentanyl (pharmaceutical and non-pharmaceutical) or fentanyl analogs for an average of 2.8 kgs per crawl. "Synthetic heroin" accounted for 33.2 % of novel synthetic opioid listings for an average 1.1 kgs per crawl with 97.7 % of listings advertised as shipped from Canada. Other novel synthetic opioids (e.g., U-47,700, AP-237) represented 22 % of these listings for an average of 6.1 kgs per crawl with 97.2 % of listings advertised as shipped from China. Conclusions: Our data indicate consistent availability of a wide variety of novel synthetic opioids both in retail and wholesale-level amounts. Identification of new substances highlights the value of cryptomarket data for early warning systems of emerging substance use trends. 1. Introduction a steady increase in the number of pharmaceutical opioid-related overdose deaths (Paulozzi et al., 2006; Hall et al., 2008) as well as an The United States is experiencing the worst opioid overdose epi- increase in the prevalence of opioid use disorder (Compton and Volkow, demic in its history. The first wave of the opioid crisis is associated with 2006). The second wave of the opioid crisis was marked by the in- prescription opioids misuse. It was fueled by the increased volume of creases in heroin use, as growing numbers of individuals who abused opioid prescribing, including by general practitioners, that could be pharmaceutical opioids started transitioning to heroin, a more potent, traced back to the recognition of pain as the "fifth vital sign," increased plentiful and less costly alternative to illicit pain pills (Carlson et al., concerns about the under-treatment of pain, and more aggressive 2016; Cicero et al., 2014; Mars et al., 2014; Unick et al., 2014, 2013). marketing and distribution strategies employed by pharmaceutical Emerging data suggest that some of the measures that were designed to companies (Van Zee, 2009; Ciccarone, 2019). From the mid 1990s to curb the availability of pharmaceutical opioids, might have inad- early 2010s, the diversion and misuse of pharmaceutical opioids caused vertently accelerated transition to heroin use among individuals who ⁎ Corresponding author. E-mail address: [email protected] (F.R. Lamy). https://doi.org/10.1016/j.drugalcdep.2020.108115 Received 12 February 2020; Received in revised form 14 May 2020; Accepted 8 June 2020 Available online 12 June 2020 0376-8716/ © 2020 Elsevier B.V. All rights reserved. F.R. Lamy, et al. Drug and Alcohol Dependence 213 (2020) 108115 were dependent on pharmaceutical opioids (Castillo-Carniglia et al., beginning of 2019 (Ball et al., 2019). However, information regarding 2019). Finally, since 2013–2014, novel synthetic opioids, such as illi- the origin and type of these novel synthetic opioids are needed to citly manufactured fentanyl, fentanyl analogs (i.e., substances sharing characterize cryptomarket data related to specific types of novel syn- similar chemical structure and action as fentanyl) and other novel thetic opioids, such as specific types of fentanyl analogs and other novel synthetic opioids (e.g., U-47,700, MT-45) have emerged in the drug synthetic opioids. To establish timely and effective policy and inter- market creating what has been called a "third wave" of the opioid vention responses to the opioid crisis in the U.S., epidemiological epidemic in the US (Ciccarone, 2019; Jones et al., 2018) and exacer- monitoring systems need to be able to rapidly identify shifts in avail- bating the opioid crisis even further. ability trends of specific novel synthetic opioid products and alert In the U.S, novel synthetic opioids were responsible for 30.5 % (n = policy makers about emerging new substances. This study builds on the 74,409) of all opioid-related overdose deaths that occurred nationally eDarkTrends project that was developed to collect and process cryp- between 2010 and 2017 (Hedegaard et al., 2018). The negative impacts tomarket data on fentanyl, fentanyl analogs and other novel synthetic in some of the Northeastern and Midwestern communities were even opioids. The overall aims of this paper are to present data collected more profound (Pardo et al., 2019). For example, in Montgomery from Dream Market over 10 months, focusing on the amounts of drugs County, Ohio, about 90 % of all unintentional overdose deaths that offered for sale (in terms of number of listings and total weight avail- occurred in 2016 and 2017 tested positive for novel synthetic opioids able for purchase), prices, and information on distribution patterns in (Daniulaityte et al., 2017a,b, 2019). terms of the countries listed as shipment origin and destination. Novel synthetic opioids are a part of the larger group of new psy- choactive substances defined by the United Nations Office on Drugs and 2. Methods Crime (UNODC) as "substances of abuse, either in a pure form or a preparation, that are not controlled by the 1961 Single Convention on 2.1. Data collection Narcotic Drugs or the 1971 Convention on Psychotropic Substances, but which may pose a public health threat." Between 2010 and 2019, the eDarkTrends, a semi-automated platform, was developed to monitor European Monitoring Centre for Drug and Drug Addiction (EMCDDA) listings of fentanyl, fentanyl analogs, and other novel synthetic opioids identified 49 novel synthetic opioids in the European drug markets on cryptomarkets to assess availability trends and identify emerging (EMCDDA, 2019). Most of these substances were not "new" per se, but substances. The data presented in this paper were collected from the rather, a resurgence of substances from older biomedical literature with DreamMarket cryptomarket and covered a nearly one-year time period limited information on their side effects (Baumann et al., 2018). Al- from March 2018 to January 2019, until DreamMarket was shut down though fentanyl was part of the substances controlled under the 1961 in February 2019 (Madore, 2019). At that time, DreamMarket was the convention, and has a long history of medical use in a variety of largest existing cryptomarket with over 60,000 listings for drugs pharmaceutical forms (e.g., Duragesic transdermal system), it is in- (Knight, 2019). Although it established a ban on fentanyl and fentanyl cluded under the label of novel synthetic opioid because current in- analog listings in May of 2018 (Ball et al., 2019), data collection was creases do not involve pharmaceutical fentanyl, but are associated with maintained as the DreamMarket remained the biggest cryptomarket non-pharmaceutical fentanyl that is illicitly produced in clandestine advertising thousands of other illicit synthetic opioids, and some ven- laboratories. It also reflects the actual position of the Drug Enforcement dors continued to sell fentanyl-type drugs under other names. Agency (DEA), which considers fentanyl as the "most prevalent and Data were collected using a custom eDarkTrends web crawler de- most significant synthetic opioid threat in the United States" (DEA, veloped and maintained by the research team at the Kno.e.sis Center 2018a,b). (fourth author U.L.). A crawler is an automated script that system- There is a growing body of evidence showing that darknet markets, atically collects all the information contained on the selected websites also known as
Load more

Recommended publications
  • Euphoric Non-Fentanil Novel Synthetic Opioids on the Illicit Drugs Market
    Forensic Toxicology (2019) 37:1–16 https://doi.org/10.1007/s11419-018-0454-5 REVIEW ARTICLE The search for the “next” euphoric non‑fentanil novel synthetic opioids on the illicit drugs market: current status and horizon scanning Kirti Kumari Sharma1,2 · Tim G. Hales3 · Vaidya Jayathirtha Rao1,2 · Niamh NicDaeid4,5 · Craig McKenzie4 Received: 7 August 2018 / Accepted: 11 November 2018 / Published online: 28 November 2018 © The Author(s) 2018 Abstract Purpose A detailed review on the chemistry and pharmacology of non-fentanil novel synthetic opioid receptor agonists, particularly N-substituted benzamides and acetamides (known colloquially as U-drugs) and 4-aminocyclohexanols, developed at the Upjohn Company in the 1970s and 1980s is presented. Method Peer-reviewed literature, patents, professional literature, data from international early warning systems and drug user fora discussion threads have been used to track their emergence as substances of abuse. Results In terms of impact on drug markets, prevalence and harm, the most signifcant compound of this class to date has been U-47700 (trans-3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-methylbenzamide), reported by users to give short- lasting euphoric efects and a desire to re-dose. Since U-47700 was internationally controlled in 2017, a range of related compounds with similar chemical structures, adapted from the original patented compounds, have appeared on the illicit drugs market. Interest in a structurally unrelated opioid developed by the Upjohn Company and now known as BDPC/bromadol appears to be increasing and should be closely monitored. Conclusions International early warning systems are an essential part of tracking emerging psychoactive substances and allow responsive action to be taken to facilitate the gathering of relevant data for detailed risk assessments.
    [Show full text]
  • Pharmaceuticals Appendix
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ADAPALENE 106685-40-9 ABANOQUIL 90402-40-7 ADAPROLOL 101479-70-3 ABECARNIL 111841-85-1 ADEMETIONINE 17176-17-9 ABLUKAST 96566-25-5 ADENOSINE PHOSPHATE 61-19-8 ABUNIDAZOLE 91017-58-2 ADIBENDAN 100510-33-6 ACADESINE 2627-69-2 ADICILLIN 525-94-0 ACAMPROSATE 77337-76-9 ADIMOLOL 78459-19-5 ACAPRAZINE 55485-20-6 ADINAZOLAM 37115-32-5 ACARBOSE 56180-94-0 ADIPHENINE 64-95-9 ACEBROCHOL 514-50-1 ADIPIODONE 606-17-7 ACEBURIC ACID 26976-72-7 ADITEREN 56066-19-4 ACEBUTOLOL 37517-30-9 ADITOPRIME 56066-63-8 ACECAINIDE 32795-44-1 ADOSOPINE 88124-26-9 ACECARBROMAL 77-66-7 ADOZELESIN 110314-48-2 ACECLIDINE 827-61-2 ADRAFINIL 63547-13-7 ACECLOFENAC 89796-99-6 ADRENALONE 99-45-6 ACEDAPSONE 77-46-3 AFALANINE 2901-75-9 ACEDIASULFONE SODIUM 127-60-6 AFLOQUALONE 56287-74-2 ACEDOBEN 556-08-1 AFUROLOL 65776-67-2 ACEFLURANOL 80595-73-9 AGANODINE 86696-87-9 ACEFURTIAMINE 10072-48-7 AKLOMIDE 3011-89-0 ACEFYLLINE CLOFIBROL 70788-27-1
    [Show full text]
  • (Ph OH N N Me O YO O YO
    US 20070265293A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2007/0265293 A1 Boyd et al. (43) Pub. Date: Nov. 15, 2007 (54) (S)-N-METHYLNALTREXONE Publication Classification (76) Inventors: Thomas A. Boyd, Grandview, NY (51) Int. Cl. (US); Howard Wagoner, Warwick, NY A6II 3L/4355 (2006.01) (US); Suketu P. Sanghvi, Kendall Park, A6M II/00 (2006.01) NJ (US); Christopher Verbicky, A6M I5/08 (2006.01) Broadalbin, NY (US); Stephen 39t. 35O C Andruski, Clifton Park, NY (US) (2006.01) A6IP 3L/00 (2006.01) Correspondence Address: St. 4. CR WOLF GREENFIELD & SACKS, P.C. (2006.01) 6OO ATLANTIC AVENUE 3G (i. 308: BOSTON, MA 02210-2206 (US) A6IP 33/02 (2006.01) C07D 489/00 (2006.01) (21) Appl. No.: 11/441,452 (52) U.S. Cl. .............. 514/282; 128/200.23; 128/202.17; (22) Filed: May 25, 2006 546/45 Related U.S. Application Data (57) ABSTRACT This invention relates to S-MNTX, methods of producing (60) Provisional application No. 60/684,570, filed on May S-MNTX, pharmaceutical preparations comprising 25, 2005. S-MNTX and methods for their use. O G M Br Br e (pH OH N N Me O YO O YO OH OH R-MNTX S-MNTX Patent Application Publication Nov. 15, 2007 Sheet 1 of 6 US 2007/0265293 A1 Fig. 1 OH OH Me-N Me-N D / O O -----BBr, O O CHCI NMP, 3 AUTOCLAVE, 70'C OMe OH 1 2 Br OH As GE) G As 69 GOH Me-N ION Me-N -lass O SO EXCHANGE O SO OH OH 3 S-MNTX 1 - OXYCODONE 2 - OXYMORPHONE 3 - ODIDE SALT OF S-MNTX Fig.
    [Show full text]
  • Pharmaceutical Appendix to the Tariff Schedule 2
    Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM LIDADRONICUM 63132-38-7 ABAFUNGIN 129639-79-8 ACIDUM SALCAPROZICUM 183990-46-7 ABAMECTIN 65195-55-3 ACIDUM SALCLOBUZICUM 387825-03-8 ABANOQUIL 90402-40-7 ACIFRAN 72420-38-3 ABAPERIDONUM 183849-43-6 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABATACEPTUM 332348-12-6 ACITEMATE 101197-99-3 ABCIXIMAB 143653-53-6 ACITRETIN 55079-83-9 ABECARNIL 111841-85-1 ACIVICIN 42228-92-2 ABETIMUSUM 167362-48-3 ACLANTATE 39633-62-0 ABIRATERONE 154229-19-3 ACLARUBICIN 57576-44-0 ABITESARTAN 137882-98-5 ACLATONIUM NAPADISILATE 55077-30-0 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURINUM 178535-93-8 ACOLBIFENUM 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDUM 185106-16-5 ACAMPROSATE 77337-76-9
    [Show full text]
  • N.A.B 33,The Narcotic Drugs and Psychotropic Substances Bill For
    THE NARCOTIC DRUGS AND PSYCHOTROPIC SUBSTANCES BILL, 2021 MEMORANDUM The objects of this Bill are to— (a) provide for the functions of the Drug Enforcement Commission; (b) revise and consolidate the law relating to drugs and precursor chemicals; (c) provide for special measures relating to the prevention, treatment and rehabilitation of victims of drug abuse; (d) repeal and replace the Narcotic Drugs and Psychotropic Substances Act, 1993; (e) domesticate the Convention on Psychotropic Substances 1971, the United Nations Convention against Illicit Traffic in Nacortic Drugs and Psychotropic Substances, 1998 and the United Nations Convention against Transnational Organised Crime, 2003; and (f) provide for matters connected with, or incidental to, the foregoing L. KALALUKA, Attorney-General N.A.B. 33, 2021 14th April, 2021 Narcotic Drugs and Psychotropic [No. of 2021 3 Substances THE NARCOTIC DRUGS AND PSYCHOTROPIC SUBSTANCES BILL, 2021 ARRANGEMENT OF SECTIONS PART I PRELIMINARY PROVISIONS Section 1. Short title and commencement 2. Interpretation PART II THE DRUG ENFORCEMENT COMMISSION 3. Establishment of the Drug Enforcement Commission 4. Functions of Commission 5. Constitution of Staff Board 6. Functions of Staff Board 7. Director-General 8. Powers of Director-General 9. Deputy Director-General 10. Investigating officers and other staff 11. Identity card 12. Oath on appointment 13. Guidance by Commission 14. Report and recommendations by Commission PART III OFFENCES AND PENALTIES 15. Prohibition of trafficking in drug or precursor chemical 16. Prohibition of import or export of drugs or precursor chemical 17. Prohibition of trade in drug or precursor chemical 18. Prohibition of possession of drug or precursor chemical 19.
    [Show full text]
  • Medicines and Related Substances Act No. 101 of 1965
    MEDICINES AND RELATED SUBSTANCES ACT NO. 101 OF 1965 [View Regulation] [ASSENTED TO 19 JUNE, 1965] [DATE OF COMMENCEMENT: 1 APRIL, 1966] (Afrikaans text signed by the State President) This Act was published in Government Gazette 40869 dated 26 May, 2017. as amended by Drugs Control Amendment Act, No. 29 of 1968 Drugs Control Amendment Act, No. 88 of 1970 Drugs Laws Amendment Act, No. 95 of 1971 Drugs Control Amendment Act, No. 65 of 1974 Medicines and Related Substances Control Amendment Act, No. 19 of 1976 Health Laws Amendment Act, No. 36 of 1977 Medicines and Related Substances Control Amendment Act, No. 17 of 1979 Medicines and Related Substances Control Amendment Act, No. 20 of 1981 Transfer of Powers and Duties of the State President Act, No. 97 of 1986 [with effect from 3 October, 1986] Businesses Act, No. 71 of 1991 [with effect from 24 May, 1991] Medicines and Related Substances Control Amendment Act, No. 94 of 1991 General Law Amendment Act, No. 49 of 1996 [with effect from 4 October, 1996] Abolition of Restrictions on the Jurisdiction of Courts Act, No. 88 of 1996 [with effect from 22 November, 1996] Medicines and Related Substances Control Amendment Act, No. 90 of 1997 Medicines and Related Substances Amendment Act, No. 59 of 2002 Judicial Matters Amendment Act, No. 66 of 2008 [with effect from 17 February, 2009] Medicines and Related Substances Amendment Act No. 72 of 2008 Medicines and Related Substances Amendment Act, No. 14 of 2015 GENERAL NOTE There is a discrepancy between the English and Afrikaans texts of section 1 of Act No.
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • Infographics About Synthetic Opioids
    UNODC LEADING THE INTERGRATED GLOBAL RESPONSE TO THE OPIOID CRISIS P I L L A R 1 P I L L A R 2 P I L L A R 3 P I L L A R 4 P I L L A R 5 I N T E R N A T I O N A L L A W S T R E N G T H E N I N G C O U N T E R E A R L Y W A R N I N G A N D R A T I O N A L P R E S C R I B I N G A N D S T R E N G T H E N I N G A N D S U P P O R T I N G E N F O R C E M E N T O P E R A T I O N S N A R C O T I C C A P A C I T Y A N D T R E N D A N A L Y S I S A C C E S S T O O P I O I D S P R E V E N T I O N A N D T R E A T M E N T T O D I S R U P T T R A F F I C K I N G I N T E R N A T I O N A L C O O P E R A T I O N IDENTIFYING THE MOST PREVELANT, PERSISTANT AND HARMFUL SYNTHETIC OPIOIDS U N O D C 282 90 E A R L Y TOXICOLOGY COLLABORATING IN COUNTRIES W A R N I N G INFORMED THREATS LABORATORIES A D V I S O R Y ASSESSMENTS PHARMACOLOGICAL INFORMATION L A B O R A T O R I E S A N D D A T A P O I N T S L A B O R A T O R I E S D A T A P O I N T S G L O B A L S M A R T U P D A T E S 21,400+ 120 DATA POINTS FROM COUNTRIES SYNTHETIC SEDATIVE 74 OPIOIDS HYPNOTICS REPORTED MIRRORING TO UNODC SYNTHETIC E A R L Y OPIOID TRENDS W A R N I N G A D V I S O R Y B Y 2019 131% IN THE LAST * * 3 Y E A R S Note: * 2019 data collection not finalized LIST OF SYNTHETIC OPIOIDS REPORTED TO THE UNODC EWA FROM 2009-2019 S C H E D U L E D 2-Fluorofentanyl Furanylfentanyl 4-Fluorobutyrfentanyl Methoxyacetylfentanyl 4-Fluoroisobutyrfentanyl MT-45 S C H E D U L E I Acrylfentanyl Ocfentanil ( 1 9 6 1 ) AH-7921 Tetrahydrofuranylfentanyl Butyrfentanyl U-47700 S C H E D U L E I & I V Cyclopropylfentanyl
    [Show full text]
  • WO 2014/085719 Al 5 June 2014 (05.06.2014) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2014/085719 Al 5 June 2014 (05.06.2014) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61M 15/00 (2006.01) A24F 47/00 (2006.01) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (21) International Application Number: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, PCT/US20 13/072426 DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (22) International Filing Date: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, 27 November 2013 (27.1 1.2013) KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, (25) Filing Language: English OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, (26) Publication Language: English SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, (30) Priority Data: ZW. 61/730,738 28 November 2012 (28. 11.2012) US 61/794,601 15 March 2013 (15.03.2013) US (84) Designated States (unless otherwise indicated, for every 61/83 1,992 6 June 2013 (06.06.2013) us kind of regional protection available): ARIPO (BW, GH, 61/887,045 4 October 201 3 (04.
    [Show full text]
  • Bf2f8ee7-3380-4536-Adc9
    THE STATUTES OF THE REPUBLIC OF SINGAPORE MISUSE OF DRUGS ACT (CHAPTER 185) (Original Enactment: Act 5 of 1973) REVISED EDITION 2008 (31st March 2008) Prepared and Published by THE LAW REVISION COMMISSION UNDER THE AUTHORITY OF THE REVISED EDITION OF THE LAWS ACT (CHAPTER 275) Informal Consolidation – version in force from 1/5/2021 CHAPTER 185 2008 Ed. Misuse of Drugs Act ARRANGEMENT OF SECTIONS PART I PRELIMINARY Section 1. Short title 2. Interpretation 3. Appointment of Director and other officers of Central Narcotics Bureau 4. Advisory committees PART II OFFENCES INVOLVING CONTROLLED DRUGS AND SUBSTANCES 5. Trafficking in controlled drugs 6. Manufacture of controlled drugs 7. Import and export of controlled drugs 8. Possession and consumption of controlled drugs 8A. Consumption of drug outside Singapore by citizen or permanent resident 9. Possession of pipes, utensils, etc. 10. Cultivation of cannabis, opium and coca plants 10A. Manufacture, supply, possession, import or export of equipment, materials or substances useful for manufacture of controlled drugs 10B. Regulations on controlled equipment, material or substances 11. Responsibilities of owners, tenants, etc. 11A. Arranging or planning gatherings where controlled drugs are to be consumed or trafficked 11B. Exposing child to drugs, etc., and permitting young person to consume drugs 11C. Introducing drug trafficker to another person 11D. Instructing person to cultivate cannabis, etc., or to manufacture or consume controlled drugs, etc. 11E. Causing or procuring young person or vulnerable person to commit certain offences 1 Informal Consolidation – version in force from 1/5/2021 2008 Ed. Misuse of Drugs CAP. 185 2 Section 12.
    [Show full text]
  • The Search for the “Next” Euphoric Non-Fentanil Novel Synthetic Opioids on the Illicit Drugs Market
    University of Dundee The search for the 'next' euphoric non-fentanil novel synthetic opioids on the illicit drugs market: current status and horizon scanning Sharma, Kirti Kumari; Hales, Tim; Rao, Vaidya Jayathirtha; Nic Daeid, Niamh; McKenzie, Craig Published in: Forensic Toxicology DOI: 10.1007/s11419-018-0454-5 Publication date: 2019 Licence: CC BY Document Version Publisher's PDF, also known as Version of record Link to publication in Discovery Research Portal Citation for published version (APA): Sharma, K. K., Hales, T., Rao, V. J., Nic Daeid, N., & McKenzie, C. (2019). The search for the 'next' euphoric non-fentanil novel synthetic opioids on the illicit drugs market: current status and horizon scanning. Forensic Toxicology, 37(1), 1-16. https://doi.org/10.1007/s11419-018-0454-5 General rights Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights. • Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research. • You may not further distribute the material or use it for any profit-making activity or commercial gain. • You may freely distribute the URL identifying the publication in the public portal. Take down policy If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim. Download date: 28. Sep. 2021 Forensic Toxicology https://doi.org/10.1007/s11419-018-0454-5 REVIEW ARTICLE The search for the “next” euphoric non‑fentanil novel synthetic opioids on the illicit drugs market: current status and horizon scanning Kirti Kumari Sharma1,2 · Tim G.
    [Show full text]
  • Lamy, F., Daniulaityte, R., Barratt, M., Lokala, U., Sheth, A., & Carlson, R
    This is the peer reviewed version of the following article: Lamy, F., Daniulaityte, R., Barratt, M., Lokala, U., Sheth, A., & Carlson, R. (2020). Listed for sale: Analyzing data on fentanyl, fentanyl analogs and other novel synthetic opioids on one cryptomarket. Drug and Alcohol Dependence, 213, 108115. which has been published in final form at https://doi.org/10.1016/j.drugalcdep.2020.108115 This article may be used for non-commercial purposes in accordance with Elsevier’s Article Sharing policy and Hosting policy © 2020. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/ Journal Pre-proof Listed for sale: analyzing data on fentanyl, fentanyl analogs and other novel synthetic opioids on one cryptomarket Francois R. Lamy, Raminta Daniulaityte, Monica J. Barratt, Usha Lokala, Amit Sheth, Robert G. Carlson PII: S0376-8716(20)30280-5 DOI: https://doi.org/10.1016/j.drugalcdep.2020.108115 Reference: DAD 108115 To appear in: Drug and Alcohol Dependence Received Date: 12 February 2020 Revised Date: 14 May 2020 Accepted Date: 8 June 2020 Please cite this article as: Lamy FR, Daniulaityte R, Barratt MJ, Lokala U, Sheth A, Carlson RG, Listed for sale: analyzing data on fentanyl, fentanyl analogs and other novel synthetic opioids on one cryptomarket, Drug and Alcohol Dependence (2020), doi: https://doi.org/10.1016/j.drugalcdep.2020.108115 This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record.
    [Show full text]